Status:
WITHDRAWN
Vortioxetine for the Treatment of Hoarding Disorder
Lead Sponsor:
Noam Soreni
Conditions:
Hoarding Disorder
Eligibility:
All Genders
25-65 years
Phase:
PHASE3
Brief Summary
The present study is a single-group open-label investigation of the potential efficacy of Vortioxetine for treatment of 30 adult volunteers with Hoarding Disorder (HD) (flexible-dose study, with a tar...
Detailed Description
Hoarding disorder (HD) is a common and severe new diagnostic category. HD has two core dimensions: difficulty discarding items and the resultant clutter, which may preclude the use of living spaces fo...
Eligibility Criteria
Inclusion
- a principal DSM-5 diagnosis of HD
- SI-R score\>=40
- age between 25-65
- no other antidepressant use in the 4 weeks that precede the first Vortioxetine dose\*
- ability to provide written informed consent
- Patients on non-Vortioxetine antidepressant who are willing to participate in the study and meet all other inclusion and exclusion criteria will be offered a 4-week antidepressant wash out period.
Exclusion
- current or past diagnosis of mania/hypo-mania, psychotic disorder or a 1st-degree relative with bipolar disorder or a psychotic disorder
- past history of behavioural activation or suicidal ideations on antidepressant medication
- known hypersensitivity to Vortioxetine
- concomitant use of other antidepressants
- current participation in CBT for HD or OCD
- concomitant use of a MAO inhibitor
- known hepatic insufficiency
- pregnancy.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04035850
Start Date
August 1 2019
End Date
August 1 2021
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Joseph Healthcare
Hamilton, Ontario, Canada, L8N 3K7